Long Focus Capital Management LLC Has $39.22 Million Stock Holdings in BioNTech SE Sponsored ADR $BNTX

Long Focus Capital Management LLC boosted its position in BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 91.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 397,655 shares of the company’s stock after acquiring an additional 189,752 shares during the period. BioNTech accounts for 1.3% of Long Focus Capital Management LLC’s portfolio, making the stock its 18th largest position. Long Focus Capital Management LLC owned 0.17% of BioNTech worth $39,217,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Royal Bank of Canada lifted its position in BioNTech by 95.9% during the 1st quarter. Royal Bank of Canada now owns 7,177 shares of the company’s stock valued at $653,000 after purchasing an additional 3,514 shares during the period. NewEdge Advisors LLC acquired a new stake in shares of BioNTech during the 1st quarter worth approximately $167,000. Envestnet Asset Management Inc. raised its stake in shares of BioNTech by 20.6% during the second quarter. Envestnet Asset Management Inc. now owns 10,570 shares of the company’s stock worth $1,125,000 after buying an additional 1,808 shares during the last quarter. Allworth Financial LP raised its stake in shares of BioNTech by 1,176.8% during the second quarter. Allworth Financial LP now owns 1,213 shares of the company’s stock worth $129,000 after buying an additional 1,118 shares during the last quarter. Finally, PNC Financial Services Group Inc. lifted its holdings in BioNTech by 80.6% in the second quarter. PNC Financial Services Group Inc. now owns 1,746 shares of the company’s stock valued at $186,000 after buying an additional 779 shares during the period. 15.52% of the stock is owned by institutional investors.

BioNTech Stock Down 0.7%

Shares of NASDAQ:BNTX opened at $90.54 on Tuesday. BioNTech SE Sponsored ADR has a 52 week low of $79.52 and a 52 week high of $124.00. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.49 and a current ratio of 7.54. The company has a market capitalization of $21.73 billion, a PE ratio of -17.28 and a beta of 1.51. The company has a 50 day moving average price of $106.30 and a two-hundred day moving average price of $102.46.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. Berenberg Bank reaffirmed a “buy” rating on shares of BioNTech in a research note on Friday, January 23rd. TD Cowen cut their price target on BioNTech from $116.00 to $94.00 and set a “hold” rating on the stock in a research note on Wednesday, March 11th. Jefferies Financial Group reduced their price target on BioNTech from $151.00 to $138.00 and set a “buy” rating on the stock in a research report on Tuesday, March 10th. Raymond James Financial reaffirmed an “outperform” rating on shares of BioNTech in a research note on Tuesday, March 10th. Finally, Truist Financial set a $155.00 price objective on BioNTech in a report on Tuesday, March 10th. Twelve investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $133.73.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.